SPC :
IMIPENEM+CILASTIN/HOSPIRA PD.SOL.INF (500+500)MG/VIAL BTx5 VIALSx20ML
ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ
!"#$%&'())
())*+VIAL
, ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ
-./0" .!#$.(1)mg .#&""2!343(1)mg
%%550&5!"6$"75" "05%5"$"6%.())mg .#&
3())mg%%550&
83"$"'*.9%54!%&:
-./0" .!#$.7;mmol'1<7(mg*5!0"
=5" 4!&35""59.3$97># . !!/";
1 ΦΑΡΜΑΚΟΤΕΧΝΙΚΗ ΜΟΡΦΗ
!"#$%&
?!"%3" 343.$!@ .3" !"35!9
A ΚΛΙΝΙΚΕΣ ΠΛΗΡΟΦΟΡΙΕΣ
A Θεραπευτικές ενδείξεις
B"..0355&-.! .059
3"-9"@C.9%..43.3 &30.#5"39
'># . !!/"AA3(*:
DE .#.."3"3#"@C.
DFC.0 ."0% .!>"#&5&"%"3".34 ."0
35&
."0%$.5G.&.5&$!4%& .%54!
DH"@C. .!.&53#3.55"5"3.5
DE .#."@C.59"!"/!9"@
DE .#."@C.5"#!5"3593@%5@
B" "!.0$!&%" "&-.05&
5.5@ %&".5.!" .3@%-.@. !.55"" "0" !$.
"I05"/.0.5%.>35&!34"09C&
J.! .0%-.@.>35&!0 " !"%G.5%.%%.74
!$. "I05%$.50G.5." "4 "5. 5 ! 9
"@C.
K!# .>"5 I&". 0%&."&0.5&%9%54$!4%&
595>35&!3@ !59
A, Δοσολογία και τρόπος χορήγησης
L"%""0
1
F"%""3#%%5%.5"ImipenemCilastatinHospira
5 !"%9 .6"5& "%5&55& .#&%%550& "-
$"!&&-.0
M&.!4%%&5"ImipenemCilastatinHospira- !# .3-"!0G.5
5"56 "35&>!65&55&"09C&75" -""'* "
""@-&3.75&./!34.5"!035"%953>!"5"
%-."6'># .. 0%& !!/"AA3(*
E43.3#/&>"
=%-..0./%""34./!34.5"!0'3-!%&3!.50&
N<)mlmin<1m
,
*75%%5@."%""3%$45.0:
())mg())mg3-.;@!.O
)))mg)))mg3-.P@!.O3-.;@!.
Q%555%."@C. " !$.& "I04.0
"..#"5"/.0"5%..0&>35&!09.3!5.!&
.%-&%0' 9Pseudomonas
aeruginosa*3%. "6"C.0"@C.
' $
%.".5.!" .3"6%-..0. !.5*- !# .$"!&"65
)))mg)))mg3-.;@!.
R.09%&5&%&.0 !05&5&5:
S &3-!%&3!.50&.0T<)mlmin<1m
,
'># .K03*4
S 5"%953>!".0U<)kgM""6%%&%-..0
>!"U<)kg "!.0 ""%-.0$!&%" "@55" !359
56 ":
K!53%953>!"' kg *x 3-.!9#&%&
<) 'kg)
M#%5&%"34&.!4%%&.- !# . .!>0.5
A)))mgA)))mg&.!&%09
V./!34%.5"!0
=5"3-"!%5&.9#&%&%..43...9#&./!34
.5"!0:
K!# .. #.5&%"34&.!4%%&' $,))),)))7
1)))1)))4A)))A)))mg* "- "!"6%.%4-9
$!&%" "&-.0%.%-..0./%""34./!34.5"!0
, W 5"K037. #.55"35&".9#""%""3
%$4%6/9.5&3-!%&3!.50&5"%-."6=5"
$!"#$%&7># .B! "$"!4&%&
K03:R.9#&%&%..43...9#&./!34.5"!0
3%953>!"X<)kgY
Q"34&.!4%
%&%.%-..0
./%""34
./!34.5"!0
'mg&#!*
-!%&3!.50&'mlmin<1m
,
*
41-70 21-40 6-20
L%&%.mg'.%"%5&%.@!.*
2000/2000
3000/3000
500/500 (8)
500/500 (6)
250/250 (6)
500/500 (8)
250/250 (12)
500/500 (12)**
2
4000/4000 750/750 (8) 500/500 (6) 500/500 (12)**
YJ !# .0. .!5#!9"34.09%&5&$"!&&-.0%
%&%.%-..0.%953>!"U<)kgM""6%%&
%-..0>!"U<)kg "!.0 ""%-.0!@55"
!53%953>!"5"%-."6'%.kg*<)kg
" %%#".5&50%5"$&%& "%%54.5%5"K03
YYZ5&%&59())mg())mg$!&%" ".05%.%-..0.
3-!%&3!.50& ;#9,)mlmin<1m
,
7 "!.0 !C.
C&#"30"./%&. & 53@3!0%.9
W%-..0.3-!%&3!.50&T( ml min <1 m
,
F%-..05"0.- !# .>"ImipenemCilastatinHospira
.35.&"6%&0.5.5AP9!@
W%-..0%."6%&
=5&-.! .0%-.@.3-!%&3!.50&T(mlmin<1m
,
7"
" "0"3""6%&7$!&%" "4%5.5%%5@..%.
%-..0.3-!%&3!.50& ;#9,)mlmin<1m
,
'># .
K03*
B%"& .#&%"3&%%550& ">"5 5&
33"/"!0355&"6%&F%-.4 !# .>.
ImipenemCilastatinHospira.55&"6%&3%..%"%545
,9!@.5"$!".5!. 5" #!5&%3.3!#&
%.!0"6%&F%-..0 " ">"5%."6%&7
05.!.3.0".%5"!3%"5"3.5!3"6.!3"6%%545"
'VQ*7- !# . !3""-"65 !"%.353=%-..0%.
"6%&5"ImipenemCilastatinHospira%%55"./%"5
"/#& .!%3.0G"5"&5330"./%&. & 53@
3!0%.9'># . !!/"AA*
B#$!%54."#.0. !34@%5.%%5"65&$!4%&
5"ImipenemCilastatinHospira%.%-..0 "3" .!5"[34
6%&
M 534%.5"!0
L.%%55 !"%!"45&%&%.%-..0..9#&& 534
.5"!0'># . !!/"(,*
M39#" &-%L. 5.05 !"%!"45&%&%.
&39#"%-..0./%""34./!34.5"!0'># .
!!/"(,*
K5!3 &-%
K5!3 &-%&30X#5"
= 5!3"6%-..0&30X#5"7&%%5@.&%&.0
((4,(,(mgkg%&$"!&"6.&3-.;@!.
Q%555%."@C. " !$.& "I04.0
"..#"5"/.0"5%.5.!".0%-&5.0&>35&!09
' 9Pseudomonas
aeruginosa*3%. "6"C.0"@C.
' $%.
3
".5.!" .3"6%-..0. !.5*- !# .$"!&"65,(,(
mgkg3-.;@!.
K5!3 &-%&30U#5"
L. !$". !3433."#5&%6%5%&"%""0%.
&303595"#5"
K5!3 &-%. ./!34 % .5"!0
L. !$". !3433."#5&%6%5%&"%""0%.
5!3"6%-..0../!34%.5"!0'3!.50&"!"6
N,mgdl*\# . !!/"AA
B! "$"!4&%&
B"ImipenemCilastatinHospira- !# .%%5-.03!9-.0
.!5#!9'># . !!/";,7;13;;* !5&$"!4&%&-.
%&T())mg())mg !# .0.5.."/#>#$%&%.
%5&,)#91). 5@-.%&N())mg())mg !# .
.$6.5%.%5&A)#9;). 5@Q.%-..0 "./0%"
50355&!3.5&#$%&7"!-5&#$%&- !# .
.9-.0
4.3 Αντενδείξεις
? .!.%-&%0%5!%53#"%0.4%.3 "" 5#3"$
"/#!"5%5& !!/";
? .!.%-&%0%." ""4 "5."5>35&!3 !"5
56 "3!> .#&
Q">!4 .!.%-&%0' $/353450!%&7%">!4
.!53450!%&*%." ""4 "5."56 ">S353"6
5>35&!3"6 !"5' $ .30.43./"% "!0.*
4.4 Ειδικές προειδοποιήσεις και προφυλάξεις κατά τη χρήση
=.3
Q5&. "45&. .#&%%550&5&-.! .0.%-.4
- !# .>.5 I&&35&5&55&$!4%&.
5>35&!3"6 !"556 "3!> .#&7>%. !59
9&%">!5&55&"09C&7". "%5&50%5%&%.
"35&"5>35&!3"6 !"5.3"30"
. "4-.353%53!> .#.>354!
? .!.%-&%0
Q">!#3.0"5.-5&/!.5!%. .!.%-&%0
'/353#*#$"/.!-.0%.%-..0 -.! .0.>S
35.W5#"5!%..0 " -./%5"6%.5"
.%5"!3.%-&%0%./"!.!"K! 5&#!C&
-.! .0.. .#&%%550&7- !# .0. !"%.3534
.C#5%&%"/"! !"&"6..5!%. .!.%-&%0%.
3!> .#.7 .30.73./"% "!0.7.>S35.3
.!"'># . !!/"A1*E./%5.0.!34
4
50!%&.5"7&-.! .0 !# .
3" .0.%Οι σοβαρές αναφυλακτικές αντιδράσεις απαιτούν
άμεση επείγουσα θεραπεία.
M 53
M& 534.5"!0- !# . !3""-.05 !"%.353355&
!3.5&-.! .0. .#&%%550&3-@ !$.
30"& 5345"C35&5' 96C&%&595!%%@7
& 534. !3.33.!">"& 505*
]!4%&%.%-..0.& 534%":%.%-..0. !"2 !$"%.
& 53#5!$#- !# . !3""-.05&& 534.5"!0
355&!3.5&-.! .0. .#&%%550&L..0
!05&5& !"%!"45&%&'># . !!/"A,*
W5""0
R-.534.%&4#.%&"3%0Coombs "!.0 !"36I.35
5&!3.5&-.! .0. .#&%%550&
W5>35&!3/%
J !# .>.5 I&5"5>35&!3/%5&
.#&%%550&705.!%.35%5%. .&53#5&
G94 ! 5&#!C&" "%4 "5.. .!34-.! .0E #"7
9 .!"!%#&.%-&%0%3.3!#9 -"97 "
%$.50G"5. $>35&!3#"@C.#!5"33@%5@7
%5& .#&%%550&7- !# .. .36.5 !"%"$4M
$!4%&5& .#&%%550&..035&&5&-.! .0
5@5956 9"@C.9.35.#$.4&55" "&-.05"
-""3.09%54&.%-&%05"4 !$..& "I0
55" " - -""'*-.035&"'*-.! .0
B5$!"&$!4%&.35&"5SMRSA !"5 "!.0
..0355 !$. "I0"@C.9.MRSA4#$. ".$-.0&
. "345"%5.3.3!#...0C.B5$!"&$!4%&
"3"%%& "!.0..0355 !$. "I0
"@C.9.
^_`_+
4#$. ".$-.0&. "345"
%5.3.3!#...0C.'># . !!/"A*
W&. 0!%&.> !"[3"C6
L.%%55&55$!"&$!4%& .#&%%550&.
> !"[3"C6> !"[35!"'># . !!/"A(*
`_`ab
"05%$.5G.&.5>"533I.".>!@&3"05
#$"/.!-.0.5& .#&%%550&3%$.."5"
" "5>35&!3"6 !"5.3 "!.030.5
4 #9 .&5345&G94E0%&53>.5 I&
54&9%&%.%-..0 "./0G"!!"355&!3.
4.55&$!4%&5& .#&%%550&'># . !!/"AP*J
!# ..C.5G.55"..$."3" 45&-.! .0.
.#&%%550&35&$"!4&%&%3.3!#&-.! .0
5"
`_`ab
L.- !# .$"!&"65/!3.53
!"[5 "%5#"5& .!0%5%&
R&05
B".%%555&-.! .05&
&05
5
V./!34%.5"!0
M .#&%%550&%%%9!.6.5%.%-..0..9#&./!34
.5"!0W. -6&5..#!.. 5"VQ - !"36I"
.&%&. !"%!G.5%5&./!34.5"!07># .
!!/"A,35" 55"c.5!3.!3%6%5&d%.54
5& !!/"
.5!3.!3%6%5&
W. -6&5..#!.. 5"VQ7 9"3"34!%5&!5&57
%$53#35%5%.74. & 53#3!0%.#$"/.!-.07
05.!5#. #!>%&59%%5@.9%.9 ".0$
""%-.0>%.5&./!34.5"!035"%953"6>!"
W5#".#!..#$"/.!-.0 "%$%.%-..0.5!$#
5"VQ' $.3./3#>>.4%5"!3. & 53@3!0%.9*
34.9#&./!34.5"!0%5"" "0"- "!"6%.
%&.9-.0%%%@!.%&59$"!&"6.9"%@Q. @7
. >.53""-.053!>@5"%%5@.""%""3
%$4705.!%.5"65"%-..0'># . !!/"A,*M
5. & 534-.! .0- !# .%.$0G.5%.%-..0.
9%54. & 5345!$4
J !# . !$.05.!&. 09%&.!""3% 5@54
. & 53#3!0%.%. .9%5"6 !"5.36"
. & 53#3!0%.74 ">"55$!"&-.! .0.
/!3.53 !"[5 ".@"5"".349%&. & 53@
3!0%.9
Q. .!0 59%& "%&.9-"6.%535!"7"3904
. & 53#3!0%.7"%-..0- !# . ">"5%.
.!""34.C#5%&37..>"4&7- !# .
C.34%"5. & 534-.! .53494Q. .!0 59%& "
%.$%5"65 ! 9% 5@55"VQ7&"%""05"
- !# ..9-.043" .0
W%-..0.3-!%&3!.50&T(<1
,
.- !# .
>"7.353. !3.5
">&-"6%."6%&.5AP9!@=%-..0%."6%&7
5"%%55"./%"5"/#&
.!%3.0G"5"&5330"./%&. & 53@3!0%.9
'># . !!/"A,*
K5!3 &-%
L. !$". !3433."# "%%5"65&$!4%&5"
%. &303595"#5"4
5!3"6%-..0..9#&./!34.5"!0'3!.50&
"!"6N,+`*\# .. 0%& ! 9%5"./".5!3.!3
%6%5&
B"())+())+ .!#$.1<(+
'7;*5!0"W5- !# .>.5 I&%.%-..0
"3""-"6.345!"/4 .!"!%#& !%&I&5!0"
A( Αλληλεπιδράσεις με άλλα φαρμακευτικά προϊόντα και άλλες
μορφές αλληλεπίδρασης
6
8$"/.!-.0.3.#.. & 53#3!0%.%.%-..0 "
#>55$!"33">0!&3 .#&%%550&W55
/!3.53 !"[5.- !# .$!&%" ""6555$!"
.3535".."/." .!%3.0G.5"36"
R.9#. 0 .> !"[3"6"C#"75" "0 "!.0 #%"359
5"-.! .53"6.6!"7#$"/.!-.05> !"[3"C6
%$"!&4-&3..3!> .#.B.9#. 0 .> !"[3"6"C#"
"!.0"&4%"%.. !34#.$"5&. & 5343!0%&
Q. @7.%%55&55$!"&$!4%& .#&3> !"[3"6
"C#"> !"[3"65!0"3.353#5>35&!3#4
5. & 53#-.! .0.- !# ..C.5G"5'># . !!/"
AA*
W 5"%55"5 &353
M55$!"&$"!4&%&5>"53@.>!/!0& "!.0.%$6%.
55 &353#. !%.8$" !C. "#/"!#.0%$%&
595 &353@. !%.9 5"%55"$"!&"6.9
5 &353@ !597% .!>"#&5&>!/!0&7%.
%-..0 ">"55$!"5>35&!3"6 !"5.F
30" "!.0 "30.".5& "3.0.&"09C&7
&303.3435%5%&5"%-."67#5%@%5.&%.%/"!5"
5>"53"6%5&6C&%&5"INR'internationalnormalisedratio*.0
6%3""C""&-.0Q%55&%.$4 !3""6-&%&5"INR
355&!3.36%5.! 5&%$"!4&%&5>"53@.#
5"%55"$"!&"6."5 &353 !"5
M55$!"&$"!4&%& .#&%%550&3 !">..%0&.0$.
9 "5#.%5&.$%5&6C&%&%5. 0 .%5" %3%5"
$!"&0%.G94%5" %5& .#&M35&%&%5"6!
..!4'&S.5>"%-.0%* .#&.@-&3.%5" .!0 ";)e5&
%&5& .#&%%550&$"!&4-&3.. !">..%0&M
55$!"&$"!4&%& .#&%%550&3 !">..%0&
%0%.5. 0 .%5" %35"$!"&0%.G94%5"
%5&%%550&7..0$.30. 0!%&%5&35&%&
5&%%550&%5"6!
A; Γονιμότητα, κύηση και γαλουχία
E3"%6&
L. !$". !3.033..$...#5.5&$!4%&5&
.#&%%550&%.#3.03.
R.#5.%.#3. -43"#$".0C. !9345"C35&5
'># . !!/"(1*F&5330"5"-!9 "..0
9%5
B"ImipenemCilastatinHospira- !# .$!&%" ".05355&
!3.5&.3"%6&"55" -/."3"".05"
-30"5"#>!"
J&%
M .#&3&%%550& .33!0"5%5"&5!3%.
3!# "%5&5.Q&.@.53!4 "!!/&%&5"3-.%%553"6
6%5.! 5"%55"$"!4&%&Q. @7-.9!.05 0-"55"
-&G">!#/"-.35.-.0%.%&53# "%5&5.E&$!4%&5"
7
ImipenemCilastatinHospira3!-.0 !05&5&75"/."5"-&%"6
5" 0- !# . ""%5.0#55" -"636"5"
0
="5&5
L. !$"-#%."#%$.53.5& -4. 0!%&5&
-.! .0. .#&%%550&%5&"5&559!%.3@4
59-&3@
A< Επιδράσεις στην ικανότητα οδήγησης και χειρισμού μηχανών
L.#$" !5" "&-.0.#5.%$.53.5. !%.%5&
35&5"4&%&3$.!%"6&$@
f%5%"7 !$"3 ".. -6&5..#!..' 9 !%-4%.7
G&7 &030"* "%$.50G"5.5" !"[53 "!.0
. !%"%5&35&5"4&%&3$.!%"6&$@
3 "9%-.@'># . !!/"AP*
AP Ανεπιθύμητες ενέργειες
Q.33#.#5. " .!.><,1%-..0 "5"
$"!&4-&3.-.! .0. .#&%%550&."/.>097" "
%$/.!..%%5&53#. -6&5..#!.. "
/#!-&395"$%5" -@%$.5G...5&-.! .045
50',7)e*7!!"'7Pe*7#.5"'7(e*7.C-&')7ge*7 !.5
')7(e*7 5%&')7Ae*7. & 53#3!0%.')7Ae*'># . !!/"
AA*7G&')71e*73&%')71e*7309%&')7,e*7 &0')7,e*
K!"7" "%$/.!..5" 3#. -6&5..#!..
45/.>05-!">"/.>05'17e*7 "%5"%&.0"5&#.%&
')7<e*7.!6-&%5"%&.0"5&#.%&')7Ae*3%34!%&5&/#>
')7,e*WC4%.595!%%@5""!"635&334
/9%/5%&/#!"5. 0%&%$
F !359. -6&5..#!..#$"/.!-.0%.33#
.#5.4355&!3.5&. .!0.55&33"/"!0
Z.". -6&5..#!.. !50-.535&"!0"!3"6
%%545"3%$5&5:K"6%$#'X)*7Q$#'X))#9
U)*7Z$%$#'X)))#9U))*7Q .'X))))#9
U)))*7K"6% .'U))))*73&S9%5#'. "!"6
.35&-"6 5-#%."#*
E53-."%$5&57". -6&5..#!..
!"%G"5.%.!/-0"%%">!5&5
Κ ατηγορία
Ο ργανικού
Σ μυστή ατος
Συχνότητα Ανεπιθύμητη ενέργεια
H"@C.3
!%5@%.
Q .
I.".>!@&3"05,
3550%&
K"6
% .
%5!.5.!05
L5!$#5"
05"3
./3"6
Q$#
&9%"/0
Z$ %$# 355!" .07".5.!" .07
.3" .07-!">"35" .07
8
%%545" -!">"355!9%&
Q . 3"33"355!0
K"6
% .
"5340735%5"4
."659"%5@
L5!$#5"
"%" "&53"6
%%545"
Q .
/353#5!%.
h$5!3#
5!$#
Z$ %$#
I$3#5!$#
% .!>"#9 !%-4%.9
3%$53@35%5%.9
L5!$#5"
.!3"6
%%545"
Z$ %$#
. & 53#3!0%.7"3"34
!%5&!5&57G&7 &0
Q .
.3./" -.7 !%-&%07
.%535!"7"09%&5&
.6%&
K"6
% .
. .09%&>!%-#.
'%-#.gravis*73./0
L5!$#5"
9535"
>!0-"
Q .
@.3"4
K"6
% .
0", .>"#
!3#
5!$#
K"6
% .
39%&, 5$3!0, 0%-&
@
W.3#
5!$#
Q$# μ-!" >"/.>05
Z$ %$# 5%&
K"6
% .
.CI.
L5!$#5"
.%53"6
%%545"75"
-@!335"
.%"-9!3"
K"6
% .
6% "7 .!.!%7"%5"
/!
L5!$#5"
%5!.5.!3"6
Q$# !!"7#.5"750V50
34#.5"%$.5G..5"
/!3.53 !"[7/0.5
./0G"5%$5.!%.%-..0
.3"33"355!" .0 5%.
%-..0$9!03"33"355!" .0
"5"$"!&.05
.#&%%550&
Q . $!@%&59"5@345&
@%%
K"6
% .
"!!343"0573"3
"70%-&36%"79%%057
.!5!"/059-&@5&@%%7
C&#&%.!!"
L5!$#5"
4 5"359
$"&/!9
Q . & 534. !3., & 505
K"6
% .
3.!">" & 505
L5!$#5"
#!5"3
5" "!"
%5"6
Q$# .!-!5&5' $.C-&534*
Z$%$# 309%&73&%
Q . 5"C34. .!34.3!%&7
.""0&7%6!""StevensS
Johnson7 "6"!/".!6-&7
"/"9534.!505
K"6
.!!9%07.5>"#%5&/45"
9
% . #!5"
L5!$#5"
"%3..53"6
%%545"3
5"%.53"6
%5"6
K"6
% .
"!-!07 "-9!334
"0!% "34%54&
L5!$#59
./!@359
"!"/!9
"@
Q .
"C.0./!34. !3.7
""!0"!07 ""!07
%$!95%"6!9'30"
3.- !# .%$#.5.
5"!0*F!"5&
.#&%%550&%5
#5&./!34.5"!0
.06%3"" !"%"!%-.07
/"6%4-9 !$"4&
!"5. " !"-#5"%.
!"./!34G9-04%.
. >!%&5&./!34.5"!0
L5!$#5"
!93"
6%%545"
35"%5"6
K"6
% .
3&%0"
=.3#
5!$#3
35%5%.5&
""6$"!4&%&
Z$ %$#
!.575" 3 "3
%34!%&%5"%&.0"5&#.%&7
.!6-&%5"%&.0"5&#.%&
K"6
% .
%/"!0%5"-@!37.C%-#&%&
0
K!33#
.C.5%.
Q$#
C4%.595!%%@5"
"!"67C4%.5&334
/9%/5%&5""!"6
Z$ %$#
J.534.%&"3%0Coombsi7
!5.5#"$!" !"-!">0&7
.9#&"%/!0&7C4%.5&
$".!-!0&5""!"67C4%.5&
3!.50&5""!"67C4%.5"
G@5""!005"
K5!3 &-%
K5!34'X1&@*
Q..#5..<P 5!3"6%-..0&30X1&@7"
. -6&5..#!.. "/#!-&3%/9"6%..3.0. "
/#!-&35".43.
Αναφορά πιθανολογούμενων ανεπιθύμητων ενεργειών
M/"! -"""6.9. -6&59..!.@.5 5&
$"!4&%&.33"/"!05"/!3.53"6 !"[5".0
%&534E 5!# .5&%.$4 !3""6-&%&5&%$#%&"/#"S
36"5"/!3.53"6 !"[5"j&5.05 5"
. .50.5"5"#5&.""34 .!0-I&/#!"
" ".%4 "5. -"""6... -6&5..#!..#%95"
.-3"6%%545"/"!:E-3F!%k!397
R.%".09,PA7lmS((;,]"!7W-4B&:1),
1,)A)1P)11<7kC:1),);(Ag(P(7n%55" ":o:pppq+
10
4.9 Υπερδοσολογία
B% 5@5 .!"%""0 " "!.0./%5"6.0%.
%/90.5" !"/059. -6&59..!.@R "!.0
.!>". & 53#3!0%.7%6$%&75!"7507#.5"7
5%&7>!3!0L. !$".3# &!"/"!0.5&
5.5@ %&5& .!"%""0.5"ImipenemCilastatinHospiraM
.#&S5!"6$"%%550&.0"54f%5%"7&
$!&%5&5545&3%0%. .!0 59%& .!"%""0.
.09%54
5. ΦΑΡΜΑΚΟΛΟΓΙΚΕΣ ΙΔΙΟΤΗΤΕΣ
5.1 Φαρμακοδυναμικές ιδιότητες
k!3"-.! .53435&"!0:W5>35&!3%%5&534
$!4%&73!> #.
93ATC:J)DH(
R&$%!%&
B" "5..05 "%%553:
.#&35!"6$"%%550&%."0:35>!"
M .#&7 "/#!.5. 0%&9NSformimidoylSthienamycin7.0#
&%-.53 !9"5&-..30&75&&5!34#9%& "
!.5 5"&5".#>354!"Streptomyces
cattleya
M .#&%3.05&>35&!"35"!%&5&%5#"55&
%6-.%&5">35&!3"6355!3"65"$@5"lS-.53@3
lS!&53@>35&!09#%95&%6.%&. .30"S
.%.53# !95.r.'^s^*
M5!"6$"%%550&.0#59%537%5!#I"3
.3%5"#5&2!" . 5%&S75"./!3"6.G6" "
.5>"0G.3!" ".05& .#&Q5.!.05.."6
5>35&!34!%&3.. &!.G.5&5>35&!34!%&
5& .#&
k!3"3&534k!3"34'^t^u*%%$#5%&
K!".">S353"65>35&!3"6 !"5.75&
@! ""%3.5!@%. .#& .!>0"5&v'BNv*
#$. ".$-.05%$.50G.5.5&365.!& "5..%535&5
R&$%5"$4
M5"$4%5& .#& "!.0"/.0.5%5.C4:
R.9#& .!55&55&.C95.!34.>!&59lS
!&53@>35&!09'95&.9#& !9459
"!@*
M .#& "!.0 "3!-.0..! 5"3655!".
50.3!"4
R.9#&%#.59^s^.5& .#&
M .#&.0%5-.!4%5&!%& 5 .!%%5.!.>S
35%.7% .!>"#959 .3%@3
3./"% "!%@ " !"5 +S-.533+S
11
!&53>354!7..C0!.%&5%$.53% .>S35%.
"!"6"3!> .#.E0&-.353%..
3!> .#. !5.3/!G"%4-95"$43%5&
.#&L. !$.%5!"6.&5"$4.5C6 .#&
3 !59 93".7"3"%0.73!"03
5.5!330.
Z!.%-&%0
BEUCASTMIC!.%-&%05& .#&75"$9!%
.0%-&59'S* -.353'R* -"7#$"9.C4'#3"%&7
,<A,))*:
Enterobacteriaceae
1
: S ≤2 mg/l, R >8 mg/l
Pseudomonas spp.
2
: S ≤4 mg/l, R >8 mg/l
Acinetobacter spp.: S ≤2 mg/l, R >8 mg/l
Staphylococcusspp
1
:.>%&5&.%-&%0%5&3./"C50&
Enterococcus spp.: S ≤4 mg/l, R >8 mg/l
wbbb_
x7s77l:M.%-&%0%.>S35.5">S
"53"6%5!. 5"333""9x7s73l.C.5
5&.%-&%0%5& .30&
Streptococcus pneumoniae
4
: S ≤2 mg/l, R >2 mg/l
y"%5!. 53"33"
A
:ST,mgl7RN,mgl
Haemophilus influenzae
4
: S ≤2 mg/l, R >2 mg/l
Moraxalla catarrhalis
4
: S ≤2 mg/l, R >2 mg/l
Neisseria
gonorrhoeae:? !$". !34%5"$.05"5&
Neisseria
gonorrhoeae "5..03%5$"-.! .0. .#&
GramS-.53.!>:ST,mgl7RNPmgl
lS!&53.!>:wT,+7mNP+
Z!.%-&%0&%$.5G..5>35&!3.0&
(
:wT,
+7mNP+
E0&
^_
3
v+
-.9!"65 59$"0%5$"5&
.#&
,
B!.%-&%05&
^_`
%$.50G"5.C&#&
%$5&5-.! .0'+3-.;@!.*
1
M.%-&%059%5/"3339%53!> .#..C.5.>%&
5&.%-&%0%5&3./"C50&
A
Q5.#$&.v5# 9 5!.%-&%0.0 "6%
4.#$"3&/.!-.0F !"%"!%3""3%0.
53!">34.%-&%0%$.53." ""4 "5.5#5""%5#.$"
!# .. >"535" "5#.%. >.>9-.07-
!# . "%5#"5%..!%54!"/"!R#$! !$"
%5"$.05&3345 3!%&59. >.>9#9%5..$@.
v 9 5"5!#$"!".%-&%07- !# ./#!"59
-.353
(
B!.%-&%0 ".%$.50G"5.%3.3!#3!">3
.0&#$" !"%"!%-.0.>%&/!3"3/!3"3&53
."#3.0.C!5&5 5&35"459v
%3.3!#9.@]!&%" ""65".0& ".
/#!"5%5"35"".5!.%-&%0.0"4%5
"%&.@%.
E%-&%0
12
F. "%5&. 035&5&5"$4 "!.0 "30..9!/3
3$!"3. .#.0&3"5" 3# &!"/"!0.5&
5"$4.0. -&5#05.!5&-.! .0%">!@"@C.9
Z ".0 !05&5"7- !# .G&5.05&%>"4
. .!"@"5"5" 3. "%5&-.3535&5.0
5#5""7@%5.&$!&%5&55" !"5%.5"$%5"3 ""
56 ""@C.950-.5 /%>45&%&
Κοινά ευαίσθητα είδη:
Gram-θετικά αερόβια:
Enterococcus faecalis
Staphylococcus aureus ( .0%-&5" %5& Methicillin)*
Staphylococcus coagulase negative ( .0%-&5" %5& Methicillin)
Streptococcus agalactiae
Streptococcus pneumoniae
Streptococcus pyogenes
Streptococcus viridans group
Gram-αρνητικά αερόβια:
Citrobacter freundii
Enterobacter aerogenes
Enterobacter cloacae
Escherichia coli
Haemophilus influenzae
Klebsiella oxytoca
Klebsiella pneumoniae
Moraxella catarrhalis
Serratia marcescens
Gram-θετικά αναερόβια:
Clostridium perfringens**
Peptostreptococcus spp.**
Gram-αρνητικά αναερόβια:
Bacteroides fragilis
Bacteroides fragilis group
Fusobacterium spp.
Porphyromonas asaccharolytica
Prevotella spp.
Veillonella spp.
Είδη για τα οποία η επίκτητη αντοχή μπορεί να αποτελεί
πρόβλημα:
Gram-αρνητικά αερόβια:
Acinetobacter
baumannii
Pseudomonas
aeruginosa
Εγγενώς ανθεκτικά είδη:
Gram θετικά αερόβια:
Enterococcus faecium
Gram-αρνητικά αερόβια:
R.!3 %5.#$& Burkholderia cepacia ( !"&"#9 Pseudomonas cepacia)
Legionella spp.
Stenotrophomonas maltophilia ( !"&"#9 Xanthomonas maltophilia,
!"&"#9 Pseudomonas maltophilia)
Άλλα:
13
Chlamydia spp.
Chlamydophila spp.
Mycoplasma spp.
Ureoplasma urealyticum
Y
Z""-.353"0%5&.-30&%5/3"33".0-.353"0
%5& .#&%%550&
YY
]!&%" ".05"EUCAST35""5!.%-&%0&
%$.5G..%3.3!#.0&
5.2 Φαρμακοκινητικές ιδιότητες
n .#&
Q3.5!@%.%5" %
Q..0.-."5#7&."/#>#$%& .#&%%550&%.
%5&,). 5@"4&%.%.#%5. 0 . .#&%5" %
3." ,#9,)+5&%&59,()+,()+7
,#9(P+5&%&59())+())+73 A#9P1
+5&%&59)))+)))+B#%#%5. 0 .
.#&%5" %.5 5&$"!4&%&59%.9,()+,()
+7())+())+73)))+)))+45<71g73;;+7
5%5"0$9R.5#5"%""0.75. 0 .5& .#&%5"
%.@"5359 +45.!"%.5#%%.!#9#C
@!.
5"4
M#%.%&5& .#&.5-!@ . !95.r.%5""!.0
.!0 ",)e
\".55!" 43 ">"4
Z5$"!&.059""-.! .07& .#&.5>"0G.5%5"
./!"6 5&`oz``{EC5"3.#.354%.%5
"6!30"5 (#9A)e7.#%&35&%&(S,)e%.
/"!..#5.
M%%550&.0.3%5"#5".G6"`oz``{
3%5#. "5..%535".5>"%5& .#%
@%5.&55$!"&$"!4&%&5& .#&3%%550&. 5!# .
. 5.$-"6-.! .535>35&!3. 0 . .#&5%"
%5"6!%"3%5" %
F$!"&0%.SG945& .#&%5" %450@!
K.!0 "<)e5"$"!&"6."5>"53"6#$.35&-.0#%5
"6!.5#39!@73.45$.6%&30 .!5#!9
#33!%&%5"6!F%3.5!@%. .#&%5"6! .!#>&%
5)+#9"35@@!..5 %&())+())+
.#&%%550&B" " "5&$"!&&-.0%%&
354-&3.%5"6!95>35&!3..!"0.5>"05.73&
">"45& .#& 53 !45"%%53&.34
L. !5&!4-&3.30%%%@!.%&5& .#&%5" %4%5
"6!."%""3%$455& .#&%%550&7$"!&"6.
14
5%"%$%"3-.#C@!.7%.%-..0./%""34./!34
.5"!0
Q%550&
Q3.5!@%.%5" %
B#%5. 0 .%%550&%5" %7.5 ."/#>
#$%&5& .#&%%550&. 0,). 5730"5 ,
#9,;+5&%&59,()+,()+7 ,#9((+
5&%&59())+())+3 (;#9PP+5&%&59
)))+)))+B#%#%5. 0 .%%550&%5" %
.5 5&$"!4&%&59%.9,()+,()+7())+())+73
)))+)))+45,,7A,73<,+75%5"0$9
5"4
M#%.%&5&%%550&.5-!@ . !95.r.%5""!
.0 .!0 "A)e
\".55!" 43 ">"4
F$!"&0%.SG945&%%550&%5" %.0 .!0 "0
@!K.!0 "<)SP)e5&%&5&%%550&.0$.35&-.0
"095"%5"6!9%%550&.5)9!@ 5&$"!4&%&
5& .#&%%550&L. !"%%-&3. .!5#!9
%%550&%5"6!K.!0 ")e>!#-&3.9"VS3.5"
.5>"05&7"" "0"#$.%5534!%535&5#55&
`oz``%.%63!%&.545&%%550&M
!%535&55&`oz``S%5"./!. 4-.%5
/%""3. 0 .0".55& ">"45&%%550& 5&
33"/"!05"05"
V./!34. !3.
R.5 0./ C."/#>%&,()+,()+
.#&%%550&7& .!"$4359 5&3 6&'x|*5&
.#&C4-&3.7S/"!#77gS/"!#73,7<S/"!#%.5".4
'-!%&3!.50&'}*()SP)<1
,
*7#5!'}1)S
U()<1
,
*73%">!4'}U1)<1
,
*./!34
%.5"!075%5"0$97%.%63!%&.5"./%""34
./!34.5"!0'}NP)<1
,
*73&x|5&
%%550&C4-&3.7;S/"!#7,7)S/"!#73;7,S/"!#%.5".
4 7#5!73%">!4./!34%.5"!075%5"0$97%.
%63!%&.5"./%""34./!34.5"!0R.5 ./ C
."/#>%&,()+,()+ .#&%%550& "
$"!&4-&3.,A@!..55&"6%&7"x|5& .#&3
%%550&451<S/"!#3;AS/"!#.65.!.75%5"0$97
9%3!0-&3..5"./%""34./!34.5"!0M
35&%& 5"6!7&./!343-!%&33-!%&%5" %5&
.#&3%%550&.@-&3..C%-#%&5&./!34
.5"!0.5 ."/#>$"!4&%& .#&%%550&
W !"%!"45&%&.0 !05&5&%-..0..9#&
./!34.5"!0'># . !!/"A,*
M 534. !3.
M/!3"3&5345& .#&%.%-..0.& 534. !3.
.#$.5.3&!9-.0H95" .!"!%#">-"65"& 53"6
.5>"%"65& .#&7&/!3"3&5345&.#.5
. &!.G.5 5&& 534%.5"!0=i57.%%55
15
30 !"%!"45&"%""0%.%-..0.& 534
%.5"!0'># . !!/"A,*
K5!3"0%-..0
M#%&3-!%&'}*3"3"35"4'~`*5& .#&
45 .!0 "A(eI&5.!.%. 5!3"6%-..0'1&@#9
A.5@*%.%63!%&.5".43.Mx|5& .#&.5
$"!4&%&((+•+%953"6>!"5& .#&%%550&
%. 5!3"6%-..045 .!0 "1)eI&5.!& 5&
#3-.%&%..43. "#>0%&())+())+Q5&
I&5.!&%&7-.%&.5 $"!4&%&,(,(+•+
.#&%%550&%. 45geI&5.!& 9
%3!0-&3..5-.%&%..43. "#>0%&)))
+)))+
M39#"
Q..0&39#".-."5#'&30;(#9<(.5@.
/%""34./!34.5"!05&&305"*7&/!3"3&534
0./ C%& .#&%%550&())+())+
$"!&"6.&."/#>. 0,). 545%6/9&.54 "
#.5%.5"../!./!34%.5"!05"" "0"
.-.9!.05 !05&5&3045&"%""0F#%"$!"
&G94%5" %5& .#&3%%550&45g€<)
. 53;g€(. 575%5"0$9K" 4"%""0..0$.
30. 0!%&%5&/!3"3&534.05.5& .#&45&
%%550&73. !5&!4-&3.30%%%@!.%&5&
.#&%%550&'># . !!/"A,*
5.3 Προκλινικά δεδομένα για την ασφάλεια
B&33."#. "36 5"05.!"30"5"
-!9 ".>%&5.#5.5"C35&5. >.9%.9
3""5"C35&5
R.#5.%.G@#.C5&5"C35&5 " !"3.05 5&
.#&79."9#"%%553745 .!"!%#&%5"./!M
%$"!4&%&5&%%550&. .#&%."0:
!">.5./!"5"C3#. !%.5& .#&%.3"#
3 -43"W .C& ".0-#%& "%5&!0G.5&
%%550& !">.5&./!"5"C35&5 !">"55&
.0%""5& .#&%5%9&!33655!
Q.0.#5&5.!5"#.%&%..3""65. -43"bz+_
%5"" "0"$"!&4-&3. .#&5!"6$"%%550&%.%.
59A)A)+•+&#!'."/#>#.%&./ C%&*"4&%.%.
&5!345"C35&5% .!>"#"5".#5"7"!.C07
@.>!"%@5"7!!"7 ">"43-5"%.3 ".
.! 5@%.Z5$"!&4-&3%. .#&5!"6$"
%%550&' .!0 "))))+•+&#!4 .!0 "1/"!#5&%4-&
%%5@.&&.!4%-!@ &."/#>%&*%..3""65.
-43"bz+_.!-.">#>#$%& !"".5
5&334$!4%&%.-!@ "7 4!C..$%5&&5!34%.C0
' .!%5%3#.5"*73-"-5"5&&5#!730#.C&
5.!5"#.%&706C&%&%5& ">"4.>!69%3!53.
5"..#$"'># . !!/"A;*
16
L.#$".C$-.0.#5..&!3.%.G@ !"3.#"
C""&-.0& -5&53!3"#.%&5& .#&S%%550&
6. ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΠΛΗΡΟΦΟΡΙΕΣ
6.1 Κατάλογος εκδόχων
ZC"-!335!"
6.2 Ασυμβατότητες
W55"/!3.53 !"[. !# ..6.5.
/!3.53 !"[5.355@ "/#!"5%5& !!/"
;;
W55" !"[.#$.$&34%>55&5.353#.@%.3
&%6%5%45".- !# .0.5%.65 "5"
.!#$"R "!.09%5%"7$"!&&-.0%.~%6%5&#$%&%5"
" "0".$6.53534#9%&
W55" !"[.- !# .6.54 !"%50-.5%.
5>"53
;1 Διάρκεια ζωής
2 $!
R.5 5&%6%5%&35&!09%&:
B"%%5#"3!9#" !# .$!&%" ".05
#%9B".%"%5&.%%5&#!C&5&%6%5%&3
5"5#"5&."/#>#$%&.- !# . .!>0.5,
@!.
;A Ιδιαίτερες προφυλάξεις κατά την φύλαξη του προϊόντος
L. !$".3#"&0.54!&%&5" !"[5
R.5 5" !@5""!09%&'355&$!4%&*:
R&35I6$.5.
=5%-43./6C&.55&%6%5%&5"/!3.53"6
!"[5"7># . !!/";1
6.5 Φύση και συστατικά του περιέκτη
=/059,)ml56 "I5" "0/#!".%53 @
>!9">"56"3333& "% @.&%/!%&'56 "flip
off*
R#.-"%%3.%0:(/0$!5"3"50
17
=/059))ml56 "I5" "0/#!".%53
@ >!9">"56"3%3"6! . "% @.&%/!%&
'56 "flipoff*
R#.-"%%3.%0:/0"$!5"3"50
R "!.0&33"/"!"6."%%3.%0.
;; Ιδιαίτερες προφυλάξεις απόρριψης και άλλος χειρισμός
W%6%5%&5"."/#>"65"
B" !"[50-.5%5&"!/4C&!4%5.0!3.9%./0 "
.!#$" "%5&5 "5%5"$.0%.())mg .#&3())mg
%%550&
B"pH%5"5" !"[5"!-0G.5.C"-!335!"7
#5%@%5.565 "- !"36I"#$"pH.5C6;7(3
P7(B"pH5959.G.%&5355
.5"G"53$!&%" ""65%6/9.5..0C.B" !"[
.!#$.1<7(mg5!0"'7;mmol*
=0"$!4%&W "!!0I5.3-. "%5&5&$!&%" "&#"
65"
M%6%5%&5&3.9- !# .0.5 %-43.%&I0
$!&%" "@55"65. "/#!"5 !359B"
- !# ..#$.5" 53%95346&3%$!95%
! 5&$"!4&%&B"- !# .$!&%" ".05"
./%".0#3..6-.!"%9509
M%5-.!5&55"%%5#"65"#$.5.3&!9-.05"
.#%"$9!"6$"5!0")7ge35" "%5.!9#"
.#%"69!
W%6%5%&5"/0"59)) ml
M%6%5%&5&%5.0!3.9- !# .0.5%6/9.5
!359"&0.B"- !# .3.05#$!0.
#7/4"5 .!%"1SA. 5%%5-.0&3
B$3%.%5"$!@7 $!9"#9305!"7.. &!.G"
5&!%535&55" !"[5"
L%&
( .#&%.
mg)
Z3"65& "
!# .
!"%5.-.0'ml*
R#%&35 !"%#%&
%3#5!9%&5" !"[5"
'mgml .#&*
500 100 5
W%6%5%&5"/0"59 ,0 ml
B" .!.$."5"/0"- !# .!@.53
.50G.5%.))ml.35&"65"#$%&8
..3."5! ".0 !"%-#%.5.%5"/0" .!0 ")ml
.35&"65"#$%&W34%5.33.50%5.
5".@!& "- !"36I.%5" .!#35&5"65"#$%&
18
K!"%"$4:5".@!&. !""!0G.5 .-.0#$%&
E >.5.5&3%0 !"%-#5"53&)ml65"
#$%&.C%/0%.5. 9#$..5%5.0"5" .!.$."
5"/0"%5"5&#$%&B"0 "- !"36I.-
!# .3&-.0#$!5"0.#
-.$!&%" "0&5"/!3.53 !"[4 . !# .
"!!0 5.5%6/9.5355 "%$6"%.%$.53#5C.
7. ΚΑΤΟΧΟΣ ΤΗΣ ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ
HospiraUKLimited
Queensway
Royal Leamington Spa
Warwickshire
CV31 3RW
μ M9 #" \%0."
8. ΑΡΙΘΜΟΣ(ΟΙ) ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ
;gP<)AS)S,)
9. ΗΜΕΡΟΜΗΝΙΑ ΠΡΩΤΗΣ ΕΓΚΡΙΣΗΣ / ΑΝΑΝΕΩΣΗΣ ΤΗΣ ΑΔΕΙΑΣ
AS)S,)
10. ΗΜΕΡΟΜΗΝΙΑ ΑΝΑΘΕΩΡΗΣΗΣ ΤΟΥ ΚΕΙΜΕΝΟΥ
19
